We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+25.85%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.06B
AUM Growth
+$329M
Cap. Flow
-$217M
Cap. Flow %
-5.35%
Top 10 Hldgs %
37.39%
Holding
124
New
4
Increased
35
Reduced
29
Closed
20

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$40.6M
2
GPCR icon
Structure Therapeutics
GPCR
+$16.4M
3
CLDX icon
Celldex Therapeutics
CLDX
+$13.8M
4
BPMC
Blueprint Medicines
BPMC
+$12.7M
5
IMVT icon
Immunovant
IMVT
+$12.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$84.9M
2
HUM icon
Humana
HUM
+$62.4M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$29.6M
4
ABCM
Abcam PLC
ABCM
+$28.9M
5
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.98%
2 Consumer Staples 1.41%
3 Industrials 1.03%
4 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPRB
76
Spruce Biosciences
SPRB
$127M
$7.64M 0.19%
34,788
-1,587
-4% -$183K
RLAY icon
77
Relay Therapeutics
RLAY
$4.37B
$7.42M 0.18%
673,966
– –
FOCL
78
EDAP TMS S.A.
FOCL
$228M
$7.32M 0.18%
1,386,425
+26,425
+2% +$154K
MRSN
79
DELISTED
Mersana Therapeutics
MRSN
$7.07M 0.17%
121,871
-14,254
-10% -$573K
PLRX icon
80
Pliant Therapeutics
PLRX
$64.4M
$6.97M 0.17%
384,996
-106,225
-22% -$1.62M
OSCR icon
81
Oscar Health
OSCR
$8.54B
$6.73M 0.17%
+735,000
New +$5.07M
FULC icon
82
Fulcrum Therapeutics
FULC
$286M
$4.91M 0.12%
727,673
– –
EPIX
83
DELISTED
ESSA Pharma
EPIX
$4.47M 0.11%
677,005
– –
SGMT icon
84
Sagimet Biosciences
SGMT
$591M
$4M 0.1%
738,355
– –
AUPH icon
85
Aurinia Pharmaceuticals
AUPH
$2.06B
$3.71M 0.09%
412,570
-66,970
-14% -$552K
CYPH
86
Cypherpunk Technologies Inc
CYPH
$72.4M
$3.45M 0.09%
832,937
-241,580
-22% -$523K
ACRS icon
87
Aclaris Therapeutics
ACRS
$868M
$3.15M 0.08%
2,998,495
-961,954
-24% -$2.93M
BEAM icon
88
Beam Therapeutics
BEAM
$2.82B
$3.03M 0.07%
111,430
– –
APLT
89
DELISTED
Applied Therapeutics
APLT
$3M 0.07%
895,195
+86,386
+11% +$215K
GOSS icon
90
Gossamer Bio
GOSS
$86.1M
$2.98M 0.07%
3,266,960
– –
BMEA icon
91
Biomea Fusion
BMEA
$92.1M
$2.63M 0.06%
181,147
– –
NVAX icon
92
Novavax
NVAX
$1.3B
$2.58M 0.06%
537,625
-110,075
-17% -$674K
CGEN icon
93
Compugen
CGEN
$221M
$2.55M 0.06%
1,289,990
– –
ADAP
94
DELISTED
Adaptimmune Therapeutics
ADAP
$1.92M 0.05%
2,425,468
-362,377
-13% -$204K
VIGL
95
DELISTED
Vigil Neuroscience
VIGL
$1.6M 0.04%
471,958
– –
OKUR
96
OnKure Therapeutics
OKUR
$164M
$1.2M 0.03%
75,173
-39,146
-34% -$2.44M
VINC
97
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$1.05M 0.03%
44,586
– –
XLO icon
98
Xilio Therapeutics
XLO
$60.5M
$792K 0.02%
102,911
– –
TLPH icon
99
Talphera
TLPH
$73.2M
$233K 0.01%
316,460
– –
NUVB.WS
100
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$8.04K ﹤0.01%
134,028
– –
1 2 3
4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Rock Springs Capital Management held 124 positions worth $4.06B, up 8.8% from $3.73B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Rock Springs Capital Management withdrew a net $217M in Q4 2023, closing 20 positions and reducing 29 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $84.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Rock Springs Capital Management opened a new position in Eli Lilly worth $40.5M.

  • Rock Springs Capital Management's largest Q4 2023 buy was Eli Lilly: 69,500 shares worth $40.5M.
  • Rock Springs Capital Management added most to Celldex Therapeutics in Q4 2023, an estimated $13.8M increase.
  • Rock Springs Capital Management's biggest Q4 2023 reduction was Humana, cutting an estimated $62.4M.
  • Rock Springs Capital Management fully exited Seagen Inc. Common Stock in Q4 2023, selling an estimated $84.9M.
  • Rock Springs Capital Management's ten largest holdings make up 37% of its $4.06B portfolio in Q4 2023.
  • Rock Springs Capital Management opened 4 new positions and closed 20 in Q4 2023.
  • Rock Springs Capital Management's portfolio value rose 8.8% quarter-over-quarter to $4.06B.

Based on Rock Springs Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.